Manufacturer: Nakon Medical
Pharmaceutical name: Semaglutide
Pack: 1 vial (5 mg)
Semaglutide is a highly effective once-weekly GLP-1 receptor agonist that greatly lowers HbA1c levels, body weight, and systolic blood pressure. Nevertheless, it is linked to a higher occurrence of gastrointestinal adverse events. Further evaluation regarding pancreatitis and retinopathy is necessary through post-approval pharmacovigilance studies.
Semaglutide is categorized as a glucagon-like peptide-1 receptor agonist, abbreviated as GLP-1 RA. This medication simulates the GLP-1 hormone, which is released from the gut in response to food intake.
One function of GLP-1 is to stimulate the body to increase insulin production, thereby lowering blood sugar levels (glucose). For this reason, Semaglutide has been utilized for over 15 years to manage Type 2 diabetes.
Additionally, elevated levels of GLP-1 have an impact on brain regions that help suppress appetite and signal satiety. When combined with a healthy diet and exercise, it can lead to substantial weight loss, as well as decrease the likelihood of developing cancer, diabetes, and heart disease in individuals who are obese or overweight.
The side effects associated with semaglutide are usually mild, especially when compared to the health complications stemming from obesity and being overweight.
Individuals using semaglutide for weight management may experience:
Dizziness
Fatigue
Gastrointestinal discomfort, including diarrhea, constipation, and gas
Headaches
Stomach disturbances, such as nausea, vomiting, pain, or bloating
Gastrointestinal issues are the most frequent complaints among new users of semaglutide. However, starting with a lower dose and gradually increasing it may help alleviate these side effects.